Buckley Wealth Management LLC Sells 220 Shares of Amgen, Inc. (NASDAQ:AMGN)

Share on StockTwits

Buckley Wealth Management LLC lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,005 shares of the medical research company’s stock after selling 220 shares during the quarter. Amgen accounts for about 2.4% of Buckley Wealth Management LLC’s investment portfolio, making the stock its 14th largest position. Buckley Wealth Management LLC’s holdings in Amgen were worth $4,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of AMGN. Nuveen Asset Management LLC lifted its position in shares of Amgen by 1,334.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock worth $910,860,000 after buying an additional 4,598,329 shares during the period. Thoroughbred Financial Services LLC lifted its position in shares of Amgen by 19,447.3% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock worth $180,539,000 after buying an additional 1,796,156 shares during the period. BlackRock Inc. lifted its position in shares of Amgen by 3.4% during the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after buying an additional 1,585,911 shares during the period. Ruffer LLP bought a new position in shares of Amgen during the 2nd quarter worth approximately $192,788,000. Finally, Beutel Goodman & Co Ltd. lifted its position in shares of Amgen by 50.5% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 1,100,511 shares of the medical research company’s stock worth $154,859,000 after buying an additional 369,142 shares during the period. Institutional investors and hedge funds own 76.24% of the company’s stock.

A number of research firms recently weighed in on AMGN. Mizuho reaffirmed a “hold” rating and set a $212.00 price target on shares of Amgen in a report on Sunday, September 29th. Cowen set a $231.00 price target on Amgen and gave the company a “buy” rating in a report on Sunday, September 29th. Cantor Fitzgerald set a $230.00 price target on Amgen and gave the company a “hold” rating in a report on Monday, September 30th. Credit Suisse Group reaffirmed an “outperform” rating and set a $225.00 price target (up from $202.00) on shares of Amgen in a report on Friday, August 16th. Finally, Wells Fargo & Co reaffirmed a “market perform” rating and set a $220.00 price target (up from $202.00) on shares of Amgen in a report on Tuesday, August 27th. They noted that the move was a valuation call. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $217.41.

In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total value of $387,160.00. Following the completion of the sale, the director now directly owns 16,436 shares of the company’s stock, valued at approximately $3,181,680.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The disclosure for this sale can be found here. Insiders sold a total of 17,851 shares of company stock valued at $3,671,900 over the last three months. Insiders own 0.25% of the company’s stock.

AMGN stock traded up $2.12 during midday trading on Friday, reaching $200.80. 2,367,190 shares of the company’s stock traded hands, compared to its average volume of 2,465,687. The company has a 50-day simple moving average of $199.57 and a two-hundred day simple moving average of $186.20. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $211.90. The company has a market cap of $117.59 billion, a price-to-earnings ratio of 13.94, a PEG ratio of 2.55 and a beta of 1.11. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period last year, the firm earned $3.83 EPS. Equities research analysts forecast that Amgen, Inc. will post 14.31 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Why is insider trading harmful?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.